RT Journal Article
SR Electronic
T1 Risk Factors for Pericardial Effusion in Patients with Stage I Esophageal Cancer Treated with Chemoradiotherapy
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 7389
OP 7393
VO 34
IS 12
A1 KEISUKE TAMARI
A1 FUMIAKI ISOHASHI
A1 YUICHI AKINO
A1 OSAMU SUZUKI
A1 YUJI SEO
A1 YASUO YOSHIOKA
A1 YOSHITO HAYASHI
A1 TSUTOMU NISHIDA
A1 TETSUO TAKEHARA
A1 MASAKI MORI
A1 YUICHIRO DOKI
A1 KAZUHIKO OGAWA
YR 2014
UL http://ar.iiarjournals.org/content/34/12/7389.abstract
AB Aim: We investigated clinical and dosimetric factors influencing the risk of developing pericardial effusion (PCE) in patients with Stage I esophageal cancer undergoing definitive chemoradiotherapy. Patients and Methods: Sixty-nine patients with Stage I esophageal cancer who underwent definitive chemoradiotherapy were retrospectively analyzed. Treatment comprised of three-dimensional conformal radiotherapy (60 Gy in 30 fractions) with concurrent chemotherapy. Clinical and dosimetric factors associated with PCE development were analyzed. Results: The median follow-up was 37 months (range=8-111 months); the crude PCE incidence rate was 52.2%. Grade 2 and 3 incidence rate was 47.8% and 4.3%, respectively. The median time to PCE onset was 5.7 months after radiotherapy. In multivariate analysis, pericardial V30 ≥41.6%, age ≥66 years, body mass index (BMI) ≥19 and diabetes mellitus (DM) were significant predictors of developing PCE. Conclusion: The present study suggests that higher pericardial V30, advanced age, high BMI and DM are risk factors for developing PCE.